Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803915 | 1.00 | DGAT1 (0.34) | DGAT1CA1CA2CA7ALDH1A1 | |
| SCHEMBL17703335 | 1.00 | DGAT1 (0.34) | DGAT1CA1CA2CA7ALDH1A1 | |
| SCHEMBL77788 | 0.84 | DGAT1 (0.40) | DGAT1CA1CA2CA7ALDH1A1 | |
| SCHEMBL796349 | 0.84 | DGAT1 (0.40) | DGAT1CA1CA2CA7ALDH1A1 | |
| SCHEMBL77789 | 0.84 | DGAT1 (0.40) | DGAT1CA1CA2CA7ALDH1A1 | |
| SCHEMBL2623071 | 0.77 | DGAT1 (0.36) | DGAT1ALDH1A1HPGD | |
| SCHEMBL11486559 | 0.77 | ALDH1A1 (0.32) | DGAT1ALDH1A1 | |
| SCHEMBL15866436 | 0.77 | DGAT1 (0.36) | DGAT1ALDH1A1HPGD | |
| SCHEMBL11486560 | 0.77 | ALDH1A1 (0.32) | DGAT1ALDH1A1 | |
| SCHEMBL14108100 | 0.76 | DGAT1 (0.32) | DGAT1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187450-B2 | Substituted pyridine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| EP-2592076-B1 | SUBSTITUTED PYRIDINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-20140213549-A9 | Substituted Pyridine Compound | UBE INDUSTRIES, LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-20140005143-A2 | Substituted PyridineCompound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-2592076-A1 | SUBSTITUTED PYRIDINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109653-A1 | Substituted Pyridine Compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-7691968-B2 | Process for the synthesis of peptides amides by side-chain attachment to a solid phase | AVECIA BIOLOGICS LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1504022-B1 | PROCESS FOR THE SYNTHESIS OF PEPTIDE AMIDES BY SIDE-CHAIN ATTACHMENT TO A SOLID PHASE | AVECIA LTD (GB) | 2006-10-11 | — | — | EP | disclosed |
| US-20050266520-A1 | Process for the synthesis of peptides | FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED (GB) | 2005-12-01 | — | — | US | disclosed |
| EP-1504022-A2 | PROCESS FOR THE SYNTHESIS OF PEPTIDE AMIDES BY SIDE-CHAIN ATTACHMENT TO A SOLID PHASE | Avecia Limited (GB) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003093302-A2 | PROCESS FOR THE SYNTHESIS OF PEPTIDES AMIDES BY SIDE-CHAIN ATTACHEMENT TO A SOLID PHASE | AVECIA LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213549-A9 | Substituted Pyridine Compound | CETP, MTTP, PRCP | DGAT1 2295/4885CA1 2349/4885CA2 607/4885 |
| US-20140005143-A2 | Substituted PyridineCompound | CETP, MTTP, CES1 | DGAT1 1356/4885CA1 3256/4885CA2 787/4885 |
| US-20130109653-A1 | Substituted Pyridine Compound | CETP, MTTP, PRCP | DGAT1 2295/4885CA1 2349/4885CA2 607/4885 |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | DGAT1 1143/4885CA1 4740/4885CA2 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.